2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Treatment Considerations, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Lymphoid Malignancies, Lymphomas, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3107 Treatment-emergent erythrocytosis after VEGFR-TKI therapy is associated with venous but not arterial thromboembolism in metastatic renal cell carcinoma

Ahmad Al-Alwan, MD, Mohammed Aloqaily, MD2, Osama Mohiuddin, MD3, Moath Albliwi, MD4, Naheed Alam, MD5
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 University of Maryland Medical Center, Baltimore, Maryland, United States
3 Integers Health, Oklahoma, Oklahoma, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Erie County Medical Center, Buffalo, New York, United States

Background: 

Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are standard therapies for metastatic renal cell carcinoma (mRCC) and are associated with treatment-emergent erythrocytosis. However, whether treatment-emergent erythrocytosis contributes to downstream vascular complications remains unclear. We evaluated the association between treatment-emergent erythrocytosis and subsequent venous thromboembolism (VTE) and arterial thromboembolism (ATE). 


Methods: 

We conducted a retrospective cohort study using the TriNetX US Collaborative Network. Adults with mRCC treated with axitinib, cabozantinib, lenvatinib, pazopanib, sorafenib, sunitinib, or tivozanib were included; patients with polycythemia vera or familial erythrocytosis were excluded. Treatment-emergent erythrocytosis was defined as a pretreatment hematocrit ≤47.9% followed by at least one hematocrit ≥49% within 90 days of VGFR-TKI initiation. Comparators had hematocrit testing during the same period without reaching this threshold. Cohorts were matched 1:1 on more than 40 baseline characteristics, including demographics, cardiovascular and thrombotic comorbidities, metastatic sites, cancer therapies, antithrombotic use, creatinine, and platelet count. A 90 day landmark design was used to reduce immortal-time bias, with outcome assessed from day 91 through day 365. Primary outcomes were VTE and ATE; secondary outcomes were hospitalization and mortality. Sex-stratified analyses were exploratory because of limited subgroup power.


Results: 

In the matched VTE cohort of 303 pairs, the median age was 64 years. VTE occurred in 37 patients with erythrocytosis and 15 comparators (12.2% vs 5.0%, risk ratio [RR], 2.47; 95% CI, 1.38-4.40; p=0.001), with similar findings in time-to-event analysis (hazard ratio [HR], 2.49; 95% CI, 1.37-4.54; log-rank p=0.002). In the matched ATE cohort of 323 pairs, ATE occurred in 13 patients with erythrocytosis and 12 comparators (4.0% vs 3.7%; RR, 1.08; 95% CI, 0.50-2.34; HR, 1.01; 95% CI, 0.46-2.20). Hospitalization was higher with erythrocytosis in the VTE cohort (33.7% vs 24.1%; RR, 1.40, p=0.009) but not significantly different in the ATE cohort (29.1% vs 22.9%; RR, 1.27; p=0.073). Mortality did not differ significantly in either analysis. 


Conclusions: 

Among patients with mRCC who remained event-free through 90 days after VEGFR-TKI initiation, treatment-emergent erythrocytosis was associated with more than twice the risk of subsequent VTE, but not ATE. This pattern suggests a venous-predominant association rather than a generalized increase in vascular events. If validated prospectively, this routinely measured laboratory marker may help identify patients who warrant closer VTE surveillance, although it is not yet sufficient to guide thromboprophylaxis or treatment modifications.  

Ahmad Al-Alwan, MD: No relevant conflicts of interest to declare.